栄養DB
広告
研究一覧に戻る
ビタミンC2026-05

ビタミンC処理により、移植後リンパ増殖性疾患腫瘍モデルにおいて、優れた細胞傷害性と適合性を持つ腫瘍標的CAR T細胞が生成される

Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.

Rahmati Pegah, Bonifacius Agnes, Dragon Anna Christina, Malinconico Chiara ほかMolecular cancer therapeutics

AI要約

ビタミンC処理は、CAR T細胞のがん細胞と戦う能力を大幅に向上させます。これにより、CAR T細胞の数が増え、移植後リンパ増殖性疾患モデルのがん細胞にも有効で、長期的な機能も向上。CAR T細胞療法強化の有望な戦略です。

AI生成の要約です — 原文を読む

Abstract(原文)

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in hematologic malignancies but faces challenges in solid tumors and virus-associated malignancies such as posttransplant lymphoproliferative disorder (PTLD). Various strategies, including optimization of receptor design, genetic modifications addressing immunomodulatory mechanisms, and refining the manufacturing process, have been explored to overcome limited in vivo persistence and tumor infiltration, antigen escape, and the immunosuppressive tumor microenvironment. This study investigated the effect of vitamin C (vitC) conditioning on CD19-targeting CAR T cells (vitC-CAR19-T) to improve the efficacy of CAR T-cell therapy. VitC has been shown to influence immune responses through epigenetic regulation and oxidative stress reduction. Enhanced transduction efficiency and proliferative capacity by vitC conditioning resulted in a higher yield of CD4+ and CD8+ CAR19-Ts. VitC-CAR19-Ts exhibited faster and improved cytotoxic response toward CD19+ Nalm-6 cells and Epstein-Barr virus-infected B-lymphoblastoid cell lines, the in vitro model of PTLD. Increased demethylation was observed in TBX21 regions, which was in line with a type 1-like phenotype and higher expression of effector molecules such as granulysin in both CD4+ and CD8+ in vitC-CAR19-Ts, providing insights into the effects of vitC conditioning. Importantly, vitC-CAR19-Ts outperformed CAR19-Ts in long-term antigen stress assays and three-dimensional multicellular spheroid models, indicating a potentially improved in vivo functionality and tumor infiltration capacity. In summary, vitC conditioning represents a promising strategy to enhance CAR T-cell yield, cytotoxic potential, and durability, complementing existing approaches to overcome the limitations of CAR T cells in the treatment of hematologic malignancies and solid tumors.

広告

出典: PubMed (PMID: 41416402)。AI要約は情報提供のみを目的とし、医療的アドバイスを構成するものではありません。